PRKG1 and colonic neoplasm: The nonsteroidal anti‐inflammatory drug (NSAID) sulindac sulfide inhibits colon cancer cell growth by suppressing Wnt/β‐catenin signaling via the cGMP/protein kinase G (PKG) pathway 26.